8-K: Harrow Inc. Announces First-Quarter 2025 Financial Results, VEVYE Sales Surge

Harrow Inc. reports a 38% increase in first-quarter revenue, driven by strong VEVYE sales growth and the launch of the VEVYE Access for All program.

Summary

• Harrow Inc. announced its first-quarter 2025 financial results, reporting total revenues of $47.8 million, a 38% increase compared to $34.6 million in the same period last year.
• VEVYE revenues increased significantly to $21.5 million, a 35% increase from $16.0 million in the fourth quarter of 2024.
• The company reported a GAAP net loss of $(17.8) million and an adjusted EBITDA of $(2.0) million.
• Cash flow from operations reached a record high of $19.7 million.
• Harrow reaffirms its 2025 revenue target of over $280 million.
• The company's cash and cash equivalents stood at $66.7 million as of March 31, 2025.
• The VEVYE Access for All (VAFA) program, launched in mid-March, is showing promising early results, with new VEVYE prescription volumes at PhilRx more than quadrupling and prescribers increasing by over 4X.
• The company expects TRIESENCE to become one of its top three revenue-generating products in 2025, driven by recent market access wins.
• Harrow is actively engaged in discussions to refinance or repay a portion of its outstanding debt, expecting to finalize these efforts by late summer or early fall of this year.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While revenue growth and positive trends in VEVYE sales are encouraging, the reported net loss and adjusted EBITDA loss temper the overall outlook. The management's confidence in meeting the 2025 revenue target and the ongoing efforts to refinance debt contribute to a moderately positive sentiment.

Positives

• Significant revenue growth of 38% compared to the prior year's first quarter.
• Strong growth in VEVYE revenues, with a 35% increase quarter-over-quarter.
• Record-high cash flow from operations of $19.7 million.
• Promising early results from the VEVYE Access for All (VAFA) program, indicating increased market share capture and revenue growth.
• Anticipated growth in IHEEZO revenues driven by new account growth and positive physician feedback.
• Expected growth in TRIESENCE revenues due to recent market access wins and adoption by large ophthalmic groups.
• Minimal and manageable impact expected from tariffs on financial results.
• Collection of a substantial portion of accounts receivable, contributing to strong cash flow from operations.

Negatives

• GAAP net loss of $(17.8) million for the quarter.
• Adjusted EBITDA of $(2.0) million for the quarter.
• Selling, general, and administrative costs increased to $40.5 million compared to $28.8 million in the same period last year, due to seasonal expenses and increased headcount.
• Core net loss for the first quarter of 2025 was $(13.6) million compared with $(9.8) million in the prior year's first quarter.
• GAAP gross margins were 68% for the first quarter of 2025 compared to 69% in the same quarter in 2024.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement the business plan, develop and commercialize products, and identify and acquire additional products.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks and uncertainties related to pharmacy operations.
• Physician interest in and market acceptance of current and future formulations and compounding pharmacies generally.
• The potential impact of tariffs on financial results, although currently expected to be minimal.

Future Outlook

Harrow expects revenues to accelerate quarter-over-quarter and anticipates stronger performance in the second half of the year, reaffirming its 2025 revenue guidance of over $280 million. The company also intends to prioritize key drivers such as VEVYE growth, IHEEZO growth, and TRIESENCE market re-establishment.

Management Comments

• Mark L. Baum, Chief Executive Officer of Harrow, stated that the company advanced key commercial initiatives to drive 2025 demand for VEVYE, IHEEZO, and TRIESENCE.
• Mark L. Baum expressed confidence that the company is on track to meet its 2025 directional revenue guidance of more than $280 million.
• Mark L. Baum believes VEVYE will be the company's first 9-figure annual revenue product.
• Mark L. Baum stated that VEVYE is presently Harrow's most valuable asset.

Industry Context

Harrow operates in the North American eyecare pharmaceutical market, competing with other pharmaceutical companies, outsourcing facilities, and pharmacies. The company's focus on innovative ophthalmic products and strategic acquisitions positions it to capitalize on the growing demand for eyecare solutions. The success of the VAFA program and the anticipated growth of TRIESENCE reflect the company's ability to navigate the market and gain market share.

Comparison to Industry Standards

• The document mentions that VEVYE is now #1 in per-prescriber volumes for dry eye prescription products, exceeding all branded dry eye products, according to IQVIA.
• The company's expansion of its specialty distribution network and GPO agreements are aimed at improving market access for its buy and bill products, aligning with industry best practices for pharmaceutical commercialization.
• Harrow's focus on patient access and affordability through programs like VAFA is consistent with the industry's increasing emphasis on value-based care and patient-centric solutions.

Legal Proceedings

• The case of ImprimisRx, LLC v. OSRX, Inc. (OSRX) is in the final stages of litigation, and a final legal ruling is expected shortly.

Stakeholder Impact

• Shareholders can expect continued efforts to drive revenue growth and improve profitability.
• Patients will benefit from increased access to affordable ophthalmic medications through programs like VAFA.
• Employees are expected to contribute to the company's growth and success through their hard work and commitment.
• Customers (eyecare professionals) can rely on Harrow as a reliable source of high-quality ophthalmic medications.

Next Steps

• Continue to drive demand for VEVYE, IHEEZO, and TRIESENCE through commercial initiatives.
• Expand patient access to VEVYE through the VAFA program.
• Leverage the commercial platform to add new impactful ophthalmic products to the portfolio.
• Finalize efforts to refinance or repay a portion of the outstanding debt by late summer or early fall of this year.
• Continue to monitor and manage the potential impact of tariffs on financial results.
• Scale VEVYE production to meet demand and ensure against stockouts and access disruptions.

Key Dates

Keywords

VEVYE, IHEEZO, TRIESENCE, Ophthalmology, Pharmaceuticals, Revenue, EBITDA, Financial Results, Harrow, Dry Eye Disease